EFFECT OF A PPAR-A AGONIST ON THE AGE RELATED CHANGES IN MYOCARDIAL METABOLISM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 心血管疾病是老年人死亡的主要原因。正常衰老与心脏结构和功能的变化有关，这种变化加剧了与糖尿病、高血压和心力衰竭等老年人常见疾病相关的变化。我们已经证明，衰老与脂质分解代谢的相对下降以及对糖代谢支持泵功能的更高依赖有关。过氧化物酶体增殖物激活受体(PPAR)α在心脏脂肪酸氧化中起重要作用。我们假设与衰老相关的PPARα的变化对脂质利用的变化有很大贡献。在这个创新的项目中，我们将测试使用PPAR激动剂吉非罗齐治疗健康的老年组是否会部分逆转通过正电子发射断层扫描测量的与衰老相关的心脏脂质氧化下降。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular disease is a leading cause of mortality in the elderly. Normal aging is associated with changes in structure and function of heart that exacerbate changes associated with diseases such as diabetes hypertension and heart failure that are common in the elderly. We have shown aging associated with a relative decline in lipid catabolism and higher reliance on glucose metabolism to support the pump function. Perxisome proliferator activated receptor (PPAR) alpha plays an important role in cardiac fatty acid oxidation. We hypothesize that aging associated changes in PPAR alpha contribute significantly to changes in lipid utilization. In this innovative project we will test whether treatment of a healthy older group with PPAR a agonist gemfibrozil would result in partial reversal of aging associated decline in cardiac lipid oxidation measured by positron emmision tomography